Immunosenescence shapes the tumor immune microenvironment and limits PD-1/PD-L1 blockade efficacy in older patients with cancer.
Aging's impact on immune cells explains why checkpoint cancer drugs work better in younger patients—and points to fixable targets.
Immunosenescence-driven changes—thymic involution, reduced TCR diversity, SASP-mediated chronic inflammation, and immunosuppressive cell expansion—mechanistically explain the heterogeneous and often limited efficacy of PD-1/PD-L1 blockade in older cancer patients; mitochondrial dysfunction, defective autophagy, and gut microbiota dysbiosis are identified as potentially targetable modulators. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Narrative review with mechanistic synthesis
- Category
- aging_longevity
- Maturity
- Exploratory
Why it surfaced
Timely review at the intersection of aging biology and immunotherapy; directly relevant as the cancer patient population ages and checkpoint inhibitors proliferate. Frontiers in Immunology is high-impact and open-access; mechanistically comprehensive.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.